首页> Transplantation and cellular therapy> Peripheral Blood CD34 Donor Chimerism has Greater Clinical Utility Than CD3 for Detecting Relapse after Allogeneic Stem Cell Transplantation for Acute Myeloid Leukemia or Myelodysplastic Syndrome.

Peripheral Blood CD34 Donor Chimerism has Greater Clinical Utility Than CD3 for Detecting Relapse after Allogeneic Stem Cell Transplantation for Acute Myeloid Leukemia or Myelodysplastic Syndrome.

导出 LinkOut

翻译打印收藏纠错

第一作者： Tongted P,Das

第一单位： Department of Clinical Haematology, Alfred Health, Melbourne, Australia.

作者： Tongted P,Das ^[1] ; Daniel,North ^[1] ; Shaun A,Fleming ^[1] ; Joanne L C,Tan ^[1] ; Adam,Ivey ^[1] ; Nicholas J,Cummings ^[1] ; Andrew,Spencer ^[2] ; Sushrut S,Patil ^[1] ; Jacqueline M L,Widjaja ^[1] ; Michael I,Swain ^[1] ; Catherine,Bourke ^[1] ; Maureen E,O'Brien ^[1] ; David S,Kliman ^[3] ; David J,Curtis ^[4]

作者单位： Department of Clinical Haematology, Alfred Health, Melbourne, Australia. ^[1] Department of Clinical Haematology, Alfred Health, Melbourne, Australia; Australian Centre for Blood Diseases, Monash University, Melbourne, Australia. ^[2] Department of Haematology, Royal North Shore Hospital, Sydney, Australia. ^[3] Department of Clinical Haematology, Alfred Health, Melbourne, Australia; Australian Centre for Blood Diseases, Monash University, Melbourne, Australia. Electronic address: david.curtis@monash.edu. ^[4]

关键词 AML Allogeneic transplantation CD34 Donor chimerism MDS Relapse